These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33662541)

  • 1. Discovery of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors.
    Zhang Y; Xia A; Zhang S; Lin G; Liu J; Chen P; Mu B; Jiao Y; Xu W; Chen M; Li L
    Bioorg Med Chem Lett; 2021 Jun; 41():127881. PubMed ID: 33662541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers.
    Sun QZ; Lin GF; Li LL; Jin XT; Huang LY; Zhang G; Yang W; Chen K; Xiang R; Chen C; Wei YQ; Lu GW; Yang SY
    J Med Chem; 2017 Jul; 60(14):6337-6352. PubMed ID: 28692292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
    Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
    Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency.
    ElHady AK; El-Gamil DS; Chen PJ; Hwang TL; Abadi AH; Abdel-Halim M; Engel M
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33668683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Discovery of Host CLK1 Inhibitors for Influenza Treatment.
    Zu M; Li C; Fang JS; Lian WW; Liu AL; Zheng LS; Du GH
    Molecules; 2015 Nov; 20(11):19735-47. PubMed ID: 26540031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).
    Rosenthal AS; Tanega C; Shen M; Mott BT; Bougie JM; Nguyen DT; Misteli T; Auld DS; Maloney DJ; Thomas CJ
    Bioorg Med Chem Lett; 2011 May; 21(10):3152-8. PubMed ID: 21450467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.
    Lawson M; Rodrigo J; Baratte B; Robert T; Delehouzé C; Lozach O; Ruchaud S; Bach S; Brion JD; Alami M; Hamze A
    Eur J Med Chem; 2016 Nov; 123():105-114. PubMed ID: 27474927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design and appraisal of selective Cdc2-Like kinase 1 (Clk1) inhibitors as novel autophagy inducers for the treatment of acute liver injury (ALI).
    Yang T; Yang Y; Chen Y; Tang M; Shi M; Tian Y; Yuan X; Yang Z; Chen L
    Eur J Med Chem; 2023 Mar; 250():115168. PubMed ID: 36780830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.
    Murár M; Dobiaš J; Šramel P; Addová G; Hanquet G; Boháč A
    Eur J Med Chem; 2017 Jan; 126():754-761. PubMed ID: 27940419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.
    Waiker DK; Karthikeyan C; Poongavanam V; Kongsted J; Lozach O; Meijer L; Trivedi P
    Bioorg Med Chem; 2014 Mar; 22(6):1909-15. PubMed ID: 24530227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors.
    Saldivia M; Fang E; Ma X; Myburgh E; Carnielli JBT; Bower-Lepts C; Brown E; Ritchie R; Lakshminarayana SB; Chen YL; Patra D; Ornelas E; Koh HXY; Williams SL; Supek F; Paape D; McCulloch R; Kaiser M; Barrett MP; Jiricek J; Diagana TT; Mottram JC; Rao SPS
    Nat Microbiol; 2020 Oct; 5(10):1207-1216. PubMed ID: 32661312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins.
    ElHady AK; Abdel-Halim M; Abadi AH; Engel M
    J Med Chem; 2017 Jul; 60(13):5377-5391. PubMed ID: 28561591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoproteomic analysis identifies CLK1 as a novel therapeutic target in gastric cancer.
    Babu N; Pinto SM; Biswas M; Subbannayya T; Rajappa M; Mohan SV; Advani J; Rajagopalan P; Sathe G; Syed N; Radhakrishna VD; Muthusamy O; Navani S; Kumar RV; Gopisetty G; Rajkumar T; Radhakrishnan P; Thiyagarajan S; Pandey A; Gowda H; Majumder P; Chatterjee A
    Gastric Cancer; 2020 Sep; 23(5):796-810. PubMed ID: 32333232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy.
    Sako Y; Ninomiya K; Okuno Y; Toyomoto M; Nishida A; Koike Y; Ohe K; Kii I; Yoshida S; Hashimoto N; Hosoya T; Matsuo M; Hagiwara M
    Sci Rep; 2017 May; 7():46126. PubMed ID: 28555643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
    Darwish SS; Abdel-Halim M; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Sep; 157():1031-1050. PubMed ID: 30193214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
    Mariano M; Hartmann RW; Engel M
    Eur J Med Chem; 2016 Apr; 112():209-216. PubMed ID: 26896709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of influenza A virus mRNA splicing by CLK1.
    Artarini A; Meyer M; Shin YJ; Huber K; Hilz N; Bracher F; Eros D; Orfi L; Keri G; Goedert S; Neuenschwander M; von Kries J; Domovich-Eisenberg Y; Dekel N; Szabadkai I; Lebendiker M; Horváth Z; Danieli T; Livnah O; Moncorgé O; Frise R; Barclay W; Meyer TF; Karlas A
    Antiviral Res; 2019 Aug; 168():187-196. PubMed ID: 31176694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines.
    Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S
    Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.